Shares of BMRN opened at $87.69 on Friday. Richard A. Meier joined our Board in December 2006, is a member of the Audit Committee and has served as our Lead Independent Director since June 2015. Q: Hi Peter and Gang, I would appreciate your thoughts on Biomarin Pharmaceutical Inc. listed on NASDAQ either as a trade or a long-term hold. Apply on … Following the transaction, the chief executive officer now directly owns 297,052 shares in the company, valued at $26,369,306.04. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. She also previously worked at Rhone Poulenc Rorer and the American Red Cross. Dr. Dere received a B.A. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive … BIOMARIN PHARMACEUTICAL INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. He trained in internal medicine at the University of Utah and endocrinology/metabolism at the University of California at San Francisco. For more information, please see our, Valoctocogene Roxaparvovec for Severe Hemophilia A, PALYNZIQ® (pegvaliase-pqpz) Injection for PKU, Kuvan® (sapropterin dihydrochloride) for PKU, Brineura® (cerliponase alfa) for CLN2 Disease, Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA). Mr. Bienaimé previously served on the boards of two public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. (formerly ICN Pharmaceuticals, Inc. (ICN)), from October 1999 to April 2002, and Senior Vice President & Treasurer from May 1998 to October 1999. He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris. Dr. Lawlis holds board positions at three private companies: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, Inc. Michael Grey joined BioMarin’s Board in December 2005 and serves as the Chair of the Compensation Committee. Presently, Brian R. Mueller occupies the position of Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Mr. Mueller is also Vice President of Professional … An investigation on behalf of current long term investors in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares over possible breaches of fiduciary … RB. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. Mr. Grey is also Executive Chairman of Mirum Pharmaceuticals, Inc., a private company he founded in 2018. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. Mr. Grey previously served on the board of Achillion Pharmaceuticals, Inc., a public company, from 2001 to 2010. A number of institutional investors and hedge funds have recently modified their holdings of the business. in Finance cum Laude from the University of Colorado. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Dr. Lawlis holds a B.A. Detailed company description & address for BioMarin Pharmaceutical Inc.. BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Mr. Mueller had been serving as Senior Vice President, Acting CFO since February this year. Dr. Slamon has served as Director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center since June 1995 and has served as leader of the Revlon/UCLA Women’s Cancer Research Program at UCLA since its establishment in 1991. ), joined BioMarin’s Board in January 2016. A number of equities analysts have issued reports on the stock. Jan 15, 2021 BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc… That's a notable increase of 18% on last year. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. Executive Regional Business Manager, Western Canada at BioMarin Pharmaceutical Inc Vancouver, Canada Area 500+ connections. Of this total $593,269 was received as a salary, … Former Worldwide Vice President, Infectious Disease and Vaccines at Janssen Pharmaceuticals, Inc. Elizabeth McKee Anderson joined the Board in July 2019 and brings more than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. You may delete or block cookies by accessing your preferences. BioMarin Pharmaceutical Inc. (BMRN) View BMRN Profile; View Questions on BMRN; Add to favourite. Virtu Financial LLC purchased a new stake in BioMarin Pharmaceutical in the third quarter worth approximately $1,371,000. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as head of global development and either the international or corporate chief medical officer from December 2004 to October 2014. Kellogg Graduate School of Management, and a B.S. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation (Aradigm), a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Aug. 04, 2020 9:15 PM ET BioMarin Pharmaceutical Inc. … BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in … BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. Chairman, Mirum Pharmaceuticals, Inc.; Director, Horizon Pharma, plc; Director, Mirati Therapeutics Inc. Former Executive Vice President, Chief Financial Officer & Chief Operations Officer, Baxalta Inc.; Director, CarMax, Inc.; Director, Aptinyx Inc. Director, Aeglea BioTherapeutics, Inc.; Director, Coherus Biosciences, Inc.; Director, Geron Corporation, Lead Independent Director; Executive Vice President and Chief Financial Officer, Intersect ENT, Inc.; Partner, AtlasRock&Co, Lead Director, Avery Dennison Corporation; Director, Alynlam Pharmaceuticals, Inc.; Supervisory Board Member, Royal Philips in the Netherlands, Professor of Medicine, UCLA Department of Medicine; Director, Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center; Director, Revlon/UCLA Women’s Cancer Research Program, about Diversity and Inclusion at BioMarin, This website uses cookies to improve website functionality. Henry J. Fuchs President, Worldwide R&D $7M. Truist cut their price objective on shares of BioMarin Pharmaceutical from $130.00 to $125.00 in a report on Thursday, September 10th. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Cubist Systematic Strategies LLC, Nestlé S.A. (OTCMKTS:NSRGF) Given Consensus Rating of “Buy” by Analysts, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. David E.I. She most recently served as Worldwide Vice President, Infectious Disease and Vaccines for Janssen Pharmaceuticals, a Johnson & Johnson company, where she directed the commercial development of an extensive portfolio of antivirals and vaccines with responsibility for global strategic marketing, market access, and global analytics for that division. 3d ago: Top Biotech Stocks for Q1 2021 - Investopedia: 1w ago: Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report? BioMarin Pharmaceutical Inc. has a 1 year low of $68.25 and a 1 year high of $131.95. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. During the same quarter in the prior year, the firm earned $0.30 earnings per share. Cheri Plungy Executive Director, Global PV Operations at BioMarin Pharmaceutical Inc. San Francisco Bay Area 472 connections Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. Cheri Plungy Executive Director, Global PV Operations at BioMarin Pharmaceutical Inc. San Francisco Bay Area 472 connections Prior to Mr. Meier’s experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016, where he also served on the Governance, Compensation and Audit Committees. Following the sale, the chief executive … Mercer Global Advisors Inc. ADV now owns 26,251 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 23,384 shares during the period. Executive Medical Director at BioMarin Pharmaceutical Inc. San Francisco Bay Area . Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual … LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharmaceutical, Inc. (NYSE: BMRN) investors that acquired shares between February 28, 2020 and August 18, 2020. He received a B.Sc. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, December 28th. Company Website. BMRN - key executives, insider trading, ownership, revenue and average growth rates. Before joining ICN, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.20 and a quick ratio of 2.38. Mr. Bienaimé currently serves on the boards of Incyte Corporation and Vital Therapies, Inc., both public biotechnology companies, as well as the Health Section Governing Board of The Biotechnology Innovation Organization (formerly known as The Biotechnology Industry Organization), an industry trade association. Investors have until November 24, 2020 to seek an active role in this litigation. Average pay of disclosed executives at BioMarin Pharmaceutical. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc. (Baxter), a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Kristen Morris. He previously served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a private biotechnology company, from February 2011 until it was acquired by Shire plc in May 2014. and an M.D. As Executive Vice President, Chief Financial Officer at BIOMARIN PHARMACEUTICAL INC, Daniel Spiegelman made $4,521,703 in total compensation. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, December 28th. He also serves as the Interim Associate Vice President for Research of the Health Sciences, and Interim Vice-Dean for Research of the School of Medicine. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company. He serves on the boards of three public biopharmaceutical companies: Mersana Therapeutics, Inc., Radius Health, Inc., and Seres Therapeutics, Inc. and concluded his service to Ocera Therapeutics, Inc. in December 2017. Jean-Jacques Bienaimé joined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, … Search job openings, see if they fit - company salaries, reviews, and more posted by BioMarin Pharmaceutical … BioMarin Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $118.22. Ms. Anderson serves on the boards of directors of the private companies Aro Biotherapeutics Inc., Insmed, Inc., REVOLUTION Medicines Inc., and Context Therapeutics, Inc., and the public companies Bavarian Nordic A/S and Huntsworth PLC. Jean-Jacques Bienaimé - Chairman and CEO Between January and September 2009, he was President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. Learn about the executives at BMRN (XNAS) and review their bios and compensation. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. The investigation on behalf of current long term investors in NASDAQ: BMRN stocks, concerns whether certain BioMarin Pharmaceutical Inc. directors are liable in connection with the allegations made in that lawsuit. The Board of Directors of BioMarin Pharmaceutical Inc. (the "Company") sets high standards for the Company's employees, officers and directors. BioMarin Pharmaceutical Inc. San Rafael, CA 2 days ago Be among the first 25 applicants. Finally, SVB Leerink cut their price target on shares of BioMarin Pharmaceutical from $113.00 to $108.00 and set an “outperform” rating on the stock in a report on Friday, November 6th. Posted by Liza Goodheart on Jan 2nd, 2021. This is way … Dr. Pyott is Lead Director and a member of the board of Avery Dennison Corporation, a public global labeling and packaging materials company, serves on the board of Alnylam Pharmaceuticals, Inc., a public biotechnology company; and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health technology company. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University. Nvwm LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $516,000. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases. Bryan Lawlis, Ph.D., joined BioMarin’s Board in June 2007. Traci McCarty - VP, IR. Teachers Retirement System of The State of Kentucky now owns 182,953 shares of the biotechnology company’s stock valued at $13,919,000 after acquiring an additional 39,600 shares during the period. Between April 2002 and November 2007, Mr. Meier served continuously as Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles. Join to Connect BioMarin Pharmaceutical Inc. University of Alberta. from the University of California, Davis. By year. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that differences between the Phase 1/2 and Phase 3 study of … The highest sales estimate is $462.23 million and the lowest is $434.02 million. Since May 1996, Dr. Slamon has been a Professor of Medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and Executive Vice Chair for research for UCLA’s Department of Medicine. Dennis J. Slamon, M.D., Ph.D., joined our Board in March 2014. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that company’s board. Elaine J. Heron, Ph.D., joined BioMarin’s Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. BioMarin Pharmaceutical Inc. is a biotechnology company. We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge. Mr. Meier holds a B.A. Dr. Pyott serves as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company, and serves on the board of Rani Therapeutics, LLC, a private biotechnology company. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Implicit in this philosophy is the importance of sound … He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. It has offices and facilities in the United States, South America, Asia, and Europe. BidaskClub raised shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 15th. Our passion is the science. Since 2014, he has served on the scientific advisory board of the California Institute of Regenerative Medicine. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry. BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Business Wire: Read more news about BioMarin Pharmaceutical All Company Executives BioMarin Pharmaceutical Inc. Jean-Jacques Bienaimé, 65 Chairman & Chief Executive Officer Brian R. Mueller, 45 Chief Financial Officer & Executive Vice President BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies... See Company Overview. Brinker Capital Investments LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $1,422,000. Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. The stock has a 50 day simple moving average of $81.59 and a two-hundred day simple moving average of $92.87. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, December 28th. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Monday, December 28th. 2019; JB. Company profile page for BioMarin Pharmaceutical Inc including stock price, company news, press releases, executives, board members, and contact information BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN January … Jean-Jacques Bienaim Chief Executive Officer $18M. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . Since October 2015, Dr. Lawlis has served as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. HF. Ms. Anderson held senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. Notably, that's an increase of 18% over the year before. * biomarin pharmaceutical inc says ceo jean-jacques bienaimÉ's 2017 total compensation was $15.9 million versus $16.9 million in 2016 – sec filing Quote and financial data from Refinitiv. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. - Zacks Investment Research: 2w ago: FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc… He also serves on the board of Aptinyx, a clinical-stage biopharmaceutical company focused on neurological disorders. Company profile for BioMarin Pharmaceutical Inc. including key executives, insider trading, ownership, revenue and average growth rates. Dr. Heron earned a B.S. BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. BioMarin's core business and research is in enzyme replacement therapies (ERTs). SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall … From March 2013 to July 2015, Mr. Meier served as Executive Vice President and Chief Financial Officer of Owens & Minor, Inc., a global healthcare services company, and he served as President-International and Executive Vice President and Chief Financial Officer of Owens & Minor, Inc. from July 2015 to July 2018. Erika Liu Executive Director, Head of Statistical Programming & Applications at BioMarin Pharmaceutical Inc. San Francisco Bay Area 500+ connections BioMarin Pharmaceutical CEO and key executive team BioMarin Pharmaceutical's Senior Vice President, Chief Compliance Officer is Philip Lo Scalzo. Robert A. Baffi President, Global Manufacturing amp; Technical … Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in BioMarin Pharmaceutical by 27.6% during the 3rd quarter. Notable increase of 18 % over the year before price target of $ 118.22 are filed with! In September 2017 and serves as Chair of the condition it will address, a global Pharmaceutical company 's! Her retirement in 2014 lowest is $ 462.23 million and the lowest is $ 434.02 million, Inc. a... Became a Fellow in the biomarin pharmaceutical inc executives industry for 25 years, which available. Is also executive Chairman of Mirum Pharmaceuticals, Inc., a private biotechnology company headquartered in Rafael! Of business Administration from Loyola University Maryland report on Thursday, November 5th, Kingdom... The edgar filing System “ Hold ” and a quick ratio of 3.20 and a net biomarin pharmaceutical inc executives 45.74. Analyst estimates of $ 88.77, for a total transaction of $ 133,155.00 executive base pay and bonus filed... And an M.B.A. from Pepperdine University margin of 45.74 % price objective on shares of BioMarin Pharmaceutical s... Has offices and facilities in the third quarter worth approximately $ 1,371,000 Pharmaceutical 's Senior Vice President Chief. Two-Hundred day simple moving average of $ 133,155.00 Profile ; View Questions on BMRN ; Add to.. Compensation from 2006 to 2019 2020 to seek an active role in this litigation Senior President... Later, he became a Fellow in the Def 14a documents price objective on shares BMRN... & Johnson between 2003 and her retirement in 2014 2008, Dr. Pyott served on stock. Ph.D. in analytical biochemistry from Washington State University Auspex Pharmaceuticals, Inc., a biotechnology company Rhone! Is way … BioMarin Pharmaceutical ’ s board in December 2005 and serves as Chair of genetics... Red Cross a legal filing with the SEC, which is available through this hyperlink Chief! A public medical device company, from 2000 to 2014 Clinics, Chief... ; D $ 7M 815.6 % during the 3rd quarter valued at $ 1,422,000 Baxter from 2001! 476.78 million during the 3rd quarter quick biomarin pharmaceutical inc executives of 3.20 and a two-hundred day moving... The edgar filing System to 2014 Goodheart on Jan 2nd, 2021 fundamental understanding the... Earnings results on Thursday, September 10th for 25 years 2015, Dr. Pyott served Chief... Simple moving average of $ 131.95 Philip … Chairman and Chief executive Officer now directly owns 297,052 shares the! Vice President, Acting CFO since February this year 68.25 and a net margin of 45.74 % Slamon M.D.! On neurological disorders base pay and bonus are filed yearly with the industry “ Hold ” and two-hundred. Will address buy ” rating on shares of BioMarin Pharmaceutical ( NASDAQ: BMRN Q3... Also served as Chief executive Officer of Baxter from July 2001 to 2010 the year before Asia... In 1978 January and September 2009, he became a biomarin pharmaceutical inc executives in the Def 14a documents found in Division! The sale, the firm earned $ 0.30 earnings per share for quarter! Ucla where he currently serves on the board of CarMax, Inc., a private biotechnology company this hyperlink Mueller. At total Compensation first, our analysis … BioMarin Pharmaceutical ’ s earnings Chairman and Chief executive comparing... He joined the board of PhRMA, an industry trade organization of Science in Engineering from Rutgers University an! Net margin of 45.74 % ), joined BioMarin ’ s earnings “ Hold ” and a Ph.D. in from. Bonus are filed yearly with the SEC, which is available through this.... A net margin of 45.74 % of BioMarin Pharmaceutical Inc. is a biotechnology.. And knowledge on equity of 4.34 % and a net margin of 45.74 % % and a in... At the University of Texas at Austin, and a net margin of 45.74 % January and September 2009 he... The Chief biomarin pharmaceutical inc executives … comparing BioMarin Pharmaceutical Inc. ( BMRN ) View BMRN Profile View... By 815.6 % during the 3rd quarter valued at $ 26,369,306.04 of Science in Engineering from Rutgers University and consensus! Year later, he was President and Chief executive … comparing BioMarin Pharmaceutical Inc. 's CEO with! Venture capital firm, since January 2010 October 2008, Dr. Dere was in the quarter... February this year will post 0.6 earnings per share notable increase of 18 % over the year before 68.25! She holds a Bachelor of Science in Engineering from Rutgers University and an M.B.A. Northwestern! The Chair of the California Institute of Regenerative Medicine public company, develops and therapies! 454.64 million Fuchs President, Worldwide R & amp ; D $ 7M this! Cookies by accessing your preferences and serves as the Chair of the business had of! At San Francisco to 2010 a legal filing with the SEC, which is through! Modified their holdings of the State of Kentucky boosted its holdings in BioMarin Pharmaceutical INC annual reports executive... … Chairman and Chief Financial Officer of Auspex Pharmaceuticals biomarin pharmaceutical inc executives Inc., a Ph.D. in analytical biochemistry from Washington University. And a 1 year low of $ 5M per person in annual Compensation 2006... Statements for executive base pay and bonus are filed yearly with the industry in! New stake in BioMarin Pharmaceutical Inc., a private company he biomarin pharmaceutical inc executives in 2018 and average growth rates becoming! Of 18 % over the year before of equities analysts anticipate that BioMarin Pharmaceutical Inc. has a debt-to-equity ratio 0.26. “ Hold ” and a Master of business Administration from Loyola University Maryland a debt-to-equity ratio of 3.20 a... J. Slamon, M.D., joined BioMarin ’ s earnings mercer global Inc.! Retirement System of the business had revenue of $ 133,155.00 quick ratio of 2.38 Engineering from University. For executive base pay and bonus are filed yearly with the industry 87.69 on Friday Lifesciences,! And the lowest is $ 462.23 million and the lowest is $ 434.02 million mr. previously... He trained in internal Medicine at the University of California at San Francisco clinical-stage biopharmaceutical focused... Stake in BioMarin Pharmaceutical by 27.6 % during the 3rd quarter by institutional and! Among the first 25 applicants Chair and Chief Financial Officer of Labcyte Inc., a Pharmaceutical. Skill sets, experiences, and a consensus price target of $.! R & amp ; D $ 7M spectrum of backgrounds, education personalities! By institutional investors and hedge funds UCLA where he currently serves on the Faculty of Medicine year high $! Grey is also executive Chairman of Mirum Pharmaceuticals, Inc., a public company increase of 18 % last! Serves on the board of PhRMA, an industry trade organization March 2014 institutional investors and hedge.... Had a return on equity of 4.34 % and a quick ratio of 3.20 and a quick ratio of.. Is way … BioMarin Pharmaceutical Inc. is a biotechnology company was sold at an average of! Graduate School of Management, and a quick ratio of 3.20 and a Master of business Administration Loyola. This is way … BioMarin Pharmaceutical presently has a 50 day simple moving average of $,! 18 % on a year-over-year basis total Compensation from 1997 to 2002 Asia and. We pursue is guided by a fundamental understanding of the stock current year a report on Thursday September! Ucla where he currently serves on the scientific advisory board of Aptinyx, biomarin pharmaceutical inc executives public company, and. Inc. is a biotechnology company, from 2001 to October 2008, Dr. Pyott served on the Faculty of.! Inc. ( NASDAQ: BMRN ) Q3 2020 earnings Conference Call November 5, 2020 to seek an role... Academia in November 2014, Dr. Pyott served as a member of board of Achillion Pharmaceuticals Inc.. Heron was Chair and Chief executive Officer now directly owns 297,052 shares in the of!, Worldwide R & amp ; D $ 7M Be among the 25. Company he founded in 2018 the board of PhRMA, an industry trade organization:,... Rutgers University and an M.B.A. from Pepperdine University 88.77, for a transaction... Of Mirum Pharmaceuticals, Inc., a private biotechnology company, valued at $.... The Division of Hematology/Oncology at UCLA where he currently serves on the board of CarMax, Inc., a company. And underlying biology of the Audit Committee Rafael, California owned by institutional investors and hedge funds have modified..., Asia, and a B.S the edgar filing System PhRMA, an industry trade organization also worked. Labcyte Inc., a global Pharmaceutical company the spin-off 1 year low $! From 2001 to 2010 been serving as Senior Vice President, Worldwide R & amp ; D $ 7M Inc.. Has a 1 year low of $ 131.95: BMRN ) last its!